Top Markets
Coin of the day
Fennec Pharmaceuticals Inc. Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc.

FENC
Classifica tra le azioni #14209
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading... Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Prezzo delle azioni
$12.33
Ultima sincronizzazione: 2026-08-31
Capitalizzazione di mercato
$428.31M
Variazione (1 giorno)
0.49%
Variazione (1 anno)
39.01%
Paese
US
Scambia Fennec Pharmaceuticals Inc. (FENC)

Categoria

Rapporto P/B per Fennec Pharmaceuticals Inc. (FENC)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Fennec Pharmaceuticals Inc., il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Fennec Pharmaceuticals Inc. da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH